GlassScriptPhysician profile
Sandra M Wigen
NPI 1043210990
$2,572.45
in general payments reported to CMS, 2019-2025
23 companies · $315 in 2025
The $315 reported for 2025 was more than what a typical Obstetrics & Gynecology (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $182 · 2022: $659 · 2023: $706 · 2024: $711 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,647 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,646.50 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $406.98 | 2021-2025 | |
| Abbvie INC. | $271.01 | 2021-2024 | |
| Exact Sciences Corporation | $250.67 | 2023-2025 | Cologuard Collection Kit |
| Organon LLC | $204.65 | 2021-2024 | Nexplanon |
| Astellas Pharma US INC | $191.21 | 2024-2025 | Veozah |
| Sumitomo Pharma America, INC. | $175.84 | 2023-2025 | Myfembree |
| Exeltis, USA INC. | $162.18 | 2022-2025 | Slynd |
| Hologic Sales and Service, LLC | $155.03 | 2022-2025 | Aptima |
| Agile Therapeutics, INC. | $105.97 | 2021-2023 | Twirla |
| Bayer Healthcare Pharmaceuticals INC. | $103.70 | 2021-2025 | |
| Therapeuticsmd, INC. | $100.21 | 2021-2022 | |
| Coopersurgical, INC. | $85.22 | 2022-2023 | Paragard T 380a |
| Amgen INC. | $79.65 | 2022-2024 | Prolia, Evenity |
| Biogen, INC. | $54.78 | 2024-2025 | Zurzuvae |
| Myovant Sciences INC. | $40.84 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $40.51 | 2024 | Intrarosa |
| Convatec INC. | $39.76 | 2022-2024 | |
| Scynexis, INC. | $24.00 | 2022 | |
| Novo Nordisk INC | $19.71 | 2022 | |
| Evofem Biosciences, INC. | $17.54 | 2021 | |
| Medicem INC. | $16.26 | 2022 | |
| Shield Therapeutics INC | $14.73 | 2024 | |
| Merck Sharp & Dohme LLC | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Wigen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.